Eagle Health Investments LP Takes Position in Dianthus Therapeutics, Inc. $DNTH

Eagle Health Investments LP bought a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 131,344 shares of the company’s stock, valued at approximately $12,803,000. Dianthus Therapeutics comprises 2.1% of Eagle Health Investments LP’s holdings, making the stock its 20th biggest holding. Eagle Health Investments LP owned approximately 0.24% of Dianthus Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Dianthus Therapeutics during the second quarter valued at approximately $401,990,000. Vestal Point Capital LP increased its holdings in shares of Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Dianthus Therapeutics by 24.7% in the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares during the period. Finally, TCG Crossover Management LLC lifted its stake in shares of Dianthus Therapeutics by 11.7% in the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock valued at $65,975,000 after purchasing an additional 175,000 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wedbush upped their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, HC Wainwright lifted their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $124.27.

Insiders Place Their Bets

In other news, SVP Adam M. Veness sold 16,167 shares of Dianthus Therapeutics stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $110.38, for a total value of $1,784,513.46. Following the sale, the senior vice president owned 3,833 shares in the company, valued at $423,086.54. This trade represents a 80.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Marino Garcia sold 166,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the sale, the chief executive officer directly owned 65,292 shares of the company’s stock, valued at $7,058,718.12. This represents a 71.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 287,084 shares of company stock valued at $29,615,923. 3.02% of the stock is owned by company insiders.

Dianthus Therapeutics Price Performance

Shares of NASDAQ:DNTH opened at $113.70 on Thursday. Dianthus Therapeutics, Inc. has a 1 year low of $22.06 and a 1 year high of $117.88. The firm has a market capitalization of $6.22 billion, a price-to-earnings ratio of -27.40 and a beta of 1.22. The business’s 50 day moving average price is $99.51 and its 200-day moving average price is $84.41.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The company had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. On average, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.